2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, CML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5081 Brexucabtagene autoleucel as consolidation therapy in adult patients with high-risk Philadelphia (Ph)-negative B-cell acute lymphoblastic leukemia

Elias Jabbour, MD, Nitin Jain, MD2, Hannah Goulart, MD3, Jayastu Senapati, MBBS, MD, DM4, Wei Ying Jen, BM BCh, FRCPath5, Guillermo Montalban-Bravo, MD6, Alex Bataller, MD, PhD7, Fadi G. Haddad, MD8, Jo Ishizawa, MD, PhD9, Ian Bouligny, M.D.10, Kelly Sharon Chien, MD11, Abhishek Maiti, MBBS12, Maro Ohanian, DO13, Musa Yilmaz, MD14, Rebecca Garris15, Min Zhao16, Guillermo Garcia-Manero, MD17, Nicholas Short, MD18, Hagop Kantarjian, MD19
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction

Despite significant improvements in outcomes for adults with B-cell acute lymphoblastic leukemia (B-ALL) following the integration of frontline immunotherapy, patients (pts) with adverse cytomolecular features or persistent measurable residual disease (MRD) remain at high risk of relapse. Brexucabtagene autolecucel (brexu-cel) has demonstrated efficacy for pts with relapsed and/or refractory (R/R) B-ALL with better outcomes seen in pts with lower disease burden and in earlier salvage settings. We hypothesized that frontline consolidation with brexu-cel would be safe and further improve the outcomes of pts with high-risk Ph-negative B-ALL.

Methods

We conducted a phase 2 study of brexu-cel as consolidation therapy in first complete remission (CR1) for pts with Ph-negative B-cell ALL with high risk genomics, defined by the presence of KTM2A-rearrangement, complex karyotype, low hypodiplody/near triploidy, Philadelphia-chromosome-like [Ph-like] ALL, or TP53 mutation), or by the presence of persistent MRD either by multiparameter flow cytometry (MFC) or next generation sequencing (NGS). Pts received 1-2 cycles of Hyper-CVAD/mini-CVD inotuzumab ozogamicin (InO) plus blinatumomab (Blina)-based regimens followed by leukapheresis, following which they could receive further cycles of therapy prior to lymphodepletion with fludarabine-cyclophosphamide and CAR T-cell infusion.

Results

From December 2024-May 2026, 22 pts were enrolled, including 19 high-risk by cytomolecular features and 3 high-risk by persistent MRD. The median age at the time of CAR T-cell infusion was 39 years (range, 19-81); 27% >60 years old and 64% male. The following high-risk cytomolecular features were present: 5 pts with complex cytogenetics, 8 pts  with CRLF2-rearraged ALL, 2 pts with non-CRLF2 Ph-like ALL (1 with an ABL2 rearrangement, and 1 with PDGFRB rearrangement), 1 pt with KMT2A-r and 3 pts with TP53 mutations (median VAF 11%, 11 – 23%). All 3 pts enrolled with persistent MRD had concurrent IKZF1 deletions/mutations. Pts received a median of 4 cycles (2 – 8) of therapy prior to lymphodepletion, predominantly mini-CVD InO Blina, of which 17 (77%) received InO.  

At the time of lymphodepletion, all pts were in a morphologic CR, 21 pts (95%) were MRD negative by MFC, and 18 pts (82%) MRD-negative by NGS. The peak CAR T-cell expansion was 11 cells/uL (0 – 51) (assessed by flow cytometry in blood), occurring at a median time of 8 days (8 – 22) following CAR T-cell infusion. Only 1 pt did not expand; he was a 66 year old pt with complex cytogenetics and a concurrent TP53 mutation. On Day 28 following CAR T, all 22 pts (100%) were MRD-negative by NGS.

The median follow-up from the time of CAR T-cell infusion was 10 months (0.95% CI 8.29 – 13.8). The estimated 1-year EFS and OS rates are 83% and 88%, respectively. In comparison, high-risk pts who received Hyper-CVAD blina +/- InO had a 1-year EFS rate of 80% with half of pts proceeding to allogeneic stem cell transplant (allo-SCT).

At last follow-up, 17 pts (77%) remain alive in remission without subsequent allo-SCT. Two pts (9%) proceeded to allo-SCT, following CAR T-cell therapy; 1 pt had KMT2A-r and subsequently experienced NGS relapse following allo-SCT and is now receiving menin-based salvage therapy, and the second pt had CRLF2-r ALL and minimal CAR T-cell expansion (3 cells/uL); this pt remains NGS MRD-negative. Three pts (14%) relapsed without allo-SCT after a median of 5 months (range 3 – 6); all had complex cytogenetics; one pt additionally had a high VAF (81%) TP53 mutation; 1 of the relapsed pts subsequently died. Two of the 3 relapsed pts had received only 2 cycles of chemo-immunotherapy.  

Fourteen pts (48%) had CRS (all grade 1); only 1 pt (3%) experienced ICANS (grade 1). Eighteen pts (82%) had grade >3 cytopenias. By Day 30, 86% had ANC>500 cells/uL, and 64% had plt >50 x 109/L; by Day 60, 90% had ANC>500 cells/uL and 73% had plt>50 x 109/L. No infectious complications were observed.

Conclusions

We demonstrate that frontline consolidation with brexu-cel was feasible, safe and resulted in encouraging survival for pts with high-risk B-ALL. Most pts remain in durable NGS MRD-negative remissions without the need for subsequent allo-SCT, suggesting that early incorporation of CAR T-cell therapy represents a promising consolidation strategy for high-risk pts.

Elias Jabbour, MD: Ascentage - Honoraria; Pfizer - Honoraria; Takeda - Honoraria; Amgen Inc. - Honoraria; Taiho - Honoraria; Novartis - Honoraria; TGRX Pharmaceuticals - Honoraria; Adaptive Biotechnologies - Honoraria; AbbVie - Honoraria; Gilead/Kite - Honoraria; TERN - Honoraria; Autolus - Honoraria; Amgen Inc. - Research Funding; AbbVie - Research Funding; Autolus - Research Funding; Takeda - Research Funding; Pfizer - Research Funding; Taiho - Research Funding; TGRX Pharmaceuticals - Research Funding; Gilead/Kite - Research Funding; Ascentage - Research Funding; Allotera - Research Funding; Novartis - Research Funding; Adaptive Biotechnologies - Research Funding; TERN - Research Funding; Amgen Inc. - Consultancy (Includes expert testimony); Allotera - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); TGRX Pharmaceuticals - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Gilead/Kite - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Taiho - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); TERN - Consultancy (Includes expert testimony)